CredoScientia - Bibliothèque

Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.

BACKGROUND: The combination of transarterial chemoembolization (TACE), lenvatinib, and PD-1 inhibitors has shown promising efficacy in treating advanced hepatocellular carcinoma (HCC). However, the im…

Thérapies de Conversion

Su, Y., Liang, Y., Zhong, D., Chen, Y., Ma, S., Wang, M., Yang, Q., Yan, H., & Huang, X. (2026). Hepatitis B virus infection and outcomes of TACE plus lenvatinib and PD-1 inhibitor therapy in unresectable hepatocellular carcinoma: a real-world propensity score-matched study.. Front Immunol, 17, 1808956. https://doi.org/10.3389/fimmu.2026.1808956

01/01/2026 Lire →

Pathologic response and safety of preoperative treatment regimens in gastric cancer undergoing D2 gastrectomy: a real-world cohort study.

OBJECTIVE: To compare pathological response and safety among three preoperative treatment regimens-chemotherapy alone, chemotherapy plus immunotherapy, and chemotherapy plus immunotherapy and targeted…

Thérapies de Conversion

Liu, P., Li, N., Guo, J., Wang, J., Wang, Z., Zhao, G., Mou, Z., & Mao, J. (2026). Pathologic response and safety of preoperative treatment regimens in gastric cancer undergoing D2 gastrectomy: a real-world cohort study.. Front Immunol, 17, 1766793. https://doi.org/10.3389/fimmu.2026.1766793

01/01/2026 Lire →

Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1/PD-L1 inhibitors plus TKIs.

OBJECTIVE: To compare overall survival (OS) and progression-free survival (PFS) between surgical resection and non-surgical therapy in initially unresectable Cholangiocarcinoma (CCA) patients who achi…

Thérapies de Conversion

Sun, Z., Wang, Y., Chen, X., Yang, L., Li, O., Zhou, J., Tan, Z., & Peng, C. (2026). Surgery vs. non-surgery for advanced cholangiocarcinoma post-conversion therapy with PD-1/PD-L1 inhibitors plus TKIs.. Front Immunol, 17, 1753437. https://doi.org/10.3389/fimmu.2026.1753437

01/01/2026 Lire →

Response Rate Correlates with the Conversion Rate in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic or Hepatic Artery Infusion Chemotherapy: A Systematic Review.

UNLABELLED: Introduction: The appropriate regimen for induction therapy with the intent of conversion therapy for advanced hepatocellular carcinoma (HCC) is unknown. This study aimed to evaluate wheth…

Thérapies de Conversion

Okuno, M., Nishino, H., Okura, K., Ishii, T., Hashida, H., & Hatano, E. (2026). Response Rate Correlates with the Conversion Rate in Patients with Advanced Hepatocellular Carcinoma Treated with Systemic or Hepatic Artery Infusion Chemotherapy: A Systematic Review.. Dig Surg, 43(1), 23-34. https://doi.org/10.1159/000550237

01/01/2026 Lire →

Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.

BACKGROUND: Patients with unresectable locally advanced esophageal squamous cell carcinoma (ESCC) face limited treatment options and poor outcomes. Preclinical evidence supports chemoimmunotherapy as …

Thérapies de Conversion

Zhu, J., Zhang, J., Ling, X., Wang, C., Yang, Y., Xin, Y., Jiang, H., Liang, H., Zhang, L., Qin, X., Lei, J., Fang, C., Yang, X., Wang, Y., Meng, W., Wang, X., Meng, H., & Ma, J. (2025). Preoperative conversion therapy of camrelizumab combined with paclitaxel and nedaplatin for unresectable advanced esophageal squamous cell carcinoma: a phase 2 study.. BMC Med, 24(1), 59. https://doi.org/10.1186/s12916-025-04592-z

28/12/2025 Lire →

Prognostic significance of Albumin-Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection.

PURPOSE: To clarify the characteristics of patients who received systemic therapy for recurrent hepatocellular carcinoma after liver resection and evaluate the associated prognostic factors.METHODS: W…

Thérapies de Conversion

Asahi, Y., Kakisaka, T., Orimo, T., Shimada, S., Nagatsu, A., Aiyama, T., Fujiyoshi, S., Sakamoto, Y., Fujii, Y., Yoshida, Y., Shichi, S., Imaizumi, K., & Taketomi, A. (2025). Prognostic significance of Albumin-Bilirubin score changes in patients treated with systemic therapy for recurrent hepatocellular carcinoma after liver resection.. Surg Today. https://doi.org/10.1007/s00595-025-03217-5

24/12/2025 Lire →

The effectiveness and safety of immune checkpoint inhibitors in conversion or neoadjuvant therapy for hepatocellular carcinoma: a meta-analysis and systematic review.

BACKGROUND: The adoption of immune checkpoint inhibitors in combination with tyrosine kinase inhibitors (TKIs) and/or local therapy, including transarterial chemoembolization (TACE) and hepatic arteri…

Thérapies de Conversion

Hu, L., Xu, Y., Qiao, Y., Wang, A., He, C., & Wang, R. (2025). The effectiveness and safety of immune checkpoint inhibitors in conversion or neoadjuvant therapy for hepatocellular carcinoma: a meta-analysis and systematic review.. BMC Cancer, 26(1), 163. https://doi.org/10.1186/s12885-025-15449-2

23/12/2025 Lire →

Resection versus microwave ablation following conversion therapy for unresectable hepatocellular carcinoma.

BACKGROUND AIMS: Conversion therapy may transform some unresectable hepatocellular carcinomas (uHCCs) into curable ones, but data remained limited comparing subsequent curative-intent treatment option…

Thérapies de Conversion

Jiang, H., Zuo, M., Wei, R., Han, J., Yao, W., Li, W., Fu, Y., Liu, W., Li, C., Lee, S., Ronot, M., Song, B., An, C., & Wu, P. (2025). Resection versus microwave ablation following conversion therapy for unresectable hepatocellular carcinoma.. Int J Surg. https://doi.org/10.1097/JS9.0000000000004486

16/12/2025 Lire →

Advances in the management of ovarian cancer liver metastasis.

Liver metastasis represents a critical challenge in cancer progression, with particularly complex therapeutic implications. In ovarian cancer patients, ovarian cancer liver metastasis (OCLM) marks a d…

Thérapies de Conversion

Li, H., Feng, Y., Wang, Z., & Li, X. (2025). Advances in the management of ovarian cancer liver metastasis.. Int J Cancer, 157(12), 2423-2433. https://doi.org/10.1002/ijc.70065

15/12/2025 Lire →

Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.

Recent advances in systemic therapies have improved clinical outcomes for patients with unresectable hepatocellular carcinoma (uHCC), as shown in randomized phase 3 clinical trials. Given the availabi…

Thérapies de Conversion

Minamiguchi, K., Irizato, M., Nakano, R., Kunichika, H., Tachiiri, T., Taiji, R., Tsuji, Y., Yasuda, S., Yoshiji, H., Sho, M., & Tanaka, T. (2025). Clinical Significance of Intratumoral Contrast Pooling on Contrast-Enhanced CT After Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.. Curr Oncol, 32(12). https://doi.org/10.3390/curroncol32120694

09/12/2025 Lire →

Screening HCC Patients Who Can Benefit from the Sequential Treatment of Conversion Therapy and Radical Surgery and Constructing a Predictive Model.

BACKGROUND/OBJECTIVE: This study aimed to develop a new nomogram to predict the likelihood of benefit for patients with advanced HCC who can benefit from the sequential treatment of conversion therapy…

Thérapies de Conversion

Liu, L., Qin, C., Lei, K., Zhang, H., & Zhang, W. (2025). Screening HCC Patients Who Can Benefit from the Sequential Treatment of Conversion Therapy and Radical Surgery and Constructing a Predictive Model.. Cancers (Basel), 17(24). https://doi.org/10.3390/cancers17243928

08/12/2025 Lire →

Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.

BACKGROUND: Conversion therapy based on vascular intervention combined with targeted immunotherapy has gradually improved treatment outcomes for hepatocellular carcinoma (HCC). Salvage surgery after c…

Thérapies de Conversion

Pang, Q., Mo, X., Tang, Z., Wei, M., Liu, D., Zhou, Z., Huang, B., Bai, T., Wang, X., & Wu, F. (2025). Safety and efficacy of salvage surgery for unresectable hepatocellular carcinoma after conversion with triple therapy: a systematic review and meta-analysis of data from Chinese patients.. World J Surg Oncol, 24(1), 21. https://doi.org/10.1186/s12957-025-04122-4

02/12/2025 Lire →